PTGS2 and colorectal cancer: Evidence supported the potential utility of non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors in reducing the incidence of adenomatous polyps and chemoprophylaxis of colorectal cancer, suggesting that COX and its products may represent a link between inflammation and colon cancer [50, 51].